Venture Partner, Third Rock Ventures

Mr. Lorence Kim’s work at Moderna raising $4.4 billion of capital for the company has helped deploy resources to discover and advance a pipeline of 24 development candidates across infectious disease, oncology, rare disease, and autoimmune disease. He has also played a significant role in helping Moderna gear up for phase 3 studies on two vaccines–including its heavily-anticipated COVID-19 vaccine. Mr. Kim is a Venture Partner at Third Rock Ventures. He has previously served as the Chief Financial Officer of Moderna from April 2014 to June 2020.